Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer

International Journal of Cancer

Volumn 133, Issue 4, 2013, Pages 984-996

  Kim, Areumnuri ^a   Lee, Jung Eun ^a   Lee, Seung Sook ^a   Kim, Cherin ^a   Lee, Sun Joo ^a   Jang, Won Suk ^a   Park, Sunhoo ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

BIM; colorectal cancer; KRAS PIK3CA mutation; PI3K MTOR

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BIM PROTEIN; BUPARLISIB; EVEROLIMUS; FLUOROURACIL; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME REPRESSION; FEMALE; GENE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENES, RAS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878860270     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28073     Document Type: Article

References (49)

1. Wolpin BM, Mayer RJ,. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134: 1296-310.
2. Bohanes P, LaBonte MJ, Winder T, et al. Predictive molecular classifiers in colorectal cancer. Semin Oncol 2011; 38: 576-87.
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45. (Pubitemid 38944402)
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42. (Pubitemid 38702844)
5. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
6. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-30.
7. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of ras. Nature 1994; 370: 527-32. (Pubitemid 24264918)
8. Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007; 121: 1771-8. (Pubitemid 47417296)
9. Khaleghpour K, Li Y, Banville D, et al. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004; 25: 241-8. (Pubitemid 38239808)
10. Shaw RJ, Cantley LC,. Ras, PI(3)K and MTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30. (Pubitemid 44050136)
11. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122: 2255-9. (Pubitemid 351542328)
12. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-54. (Pubitemid 40981849)
13. Cantley LC,. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7. (Pubitemid 34579158)
14. West KA, Castillo SS, Dennis PA,. Activation of the PI3K/AKT pathway and chemotherapeutic resistance. Drug Resist Updat 2002; 5: 234-48. (Pubitemid 36132805)
15. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177-89. (Pubitemid 34876546)
16. O'Reilly KE, Rojo F, She QB, et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res 2006; 66: 1500-8. (Pubitemid 43259931)
17. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-63.
18. Brachmann SM, Hofmann I, Schnell C, et al. Specific apoptosis induction by the dual PI3K/MTOR inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009; 106: 22299-304.
19. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010; 16: 530-40.
20. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/MTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-30.
21. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the MTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-30.
22. Dufort S, Richard MJ, de Fraipont F,. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 2009; 391: 166-8.
23. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534-41. (Pubitemid 351770297)
24. Kim A, Park S, Lee JE, et al. The dual PI3K and MTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leuk Res 2012; 36: 912-20.
25. Gomes AR, Brosens JJ, Lam EW,. Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008; 7: 3133-6.
26. van Gorp AG, Pomeranz KM, Birkenkamp KU, et al. Chronic protein kinase B (PKB/c-AKT) activation leads to apoptosis induced by oxidative stress-mediated FOXO3A transcriptional up-regulation. Cancer Res 2006; 66: 10760-9. (Pubitemid 44876971)
27. Fernandez de Mattos S, Villalonga P, Clardy J, et al. FOXO3A mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther 2008; 7: 3237-46.
28. Massague J,. G1 cell-cycle control and cancer. Nature 2004; 432: 298-306. (Pubitemid 39551657)
29. Miao J, Chen GG, Yun JP, et al. Identification and characterization of BH3 domain protein BIM and its isoforms in human hepatocellular carcinomas. Apoptosis 2007; 12: 1691-701. (Pubitemid 47108190)
30. Ambrosini G, Seelman SL, Schwartz GK,. Differentiation-related gene-1 decreases BIM stability by proteasome-mediated degradation. Cancer Res 2009; 69: 6115-21.
31. Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging. Cancer Res 2008; 68: 6598-607.
32. Bos JL,. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9. (Pubitemid 19213607)
33. Halilovic E, She QB, Ye Q, et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010; 70: 6804-14.
34. Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286-93.
35. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-6.
36. Yu K, Toral-Barza L, Shi C, et al. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 2008; 7: 307-15.
37. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin Cancer Res 2012; 18: 2257-68.
38. Accioly MT, Pacheco P, Maya-Monteiro CM, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res 2008; 68: 1732-40. (Pubitemid 351416558)
39. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-606.
40. Hanada M, Feng J, Hemmings BA,. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 2004; 1697: 3-16. (Pubitemid 38326757)
41. Whiteman EL, Cho H, Birnbaum MJ,. Role of AKT/protein kinase B in metabolism. Trends Endocrinol Metab 2002; 13: 444-51. (Pubitemid 36733939)
42. Franke TF,. PI3K/AKT: getting it right matters. Oncogene 200; 27: 6473-88.
43. Medema RH, Kops GJ, Bos JL, et al. AFX-like forkhead transcription factors mediate cell-cycle regulation by ras and PKB through p27kip1. Nature 2000; 404: 782-7. (Pubitemid 30212408)
44. Cartlidge RA, Thomas GR, Cagnol S, et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008; 21: 534-44.
45. Cai B, Chang SH, Becker EB, et al. p38 MAP kinase mediates apoptosis through phosphorylation of BIMEL at ser-65. J Biol Chem 2006; 281: 25215-22. (Pubitemid 44401908)
46. Ley R, Ewings KE, Hadfield K, et al. Regulatory phosphorylation of BIM: Sorting out the ERK from the JNK. Cell Death Differ 2005; 12: 1008-14. (Pubitemid 41065418)
47. Greenhough A, Wallam CA, Hicks DJ, et al. The proapoptotic BH3-only protein BIM is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene 2010; 29: 3398-410.
48. O'Connor L, Strasser A, O'Reilly LA, et al. BIM: a novel member of the bcl-2 family that promotes apoptosis. EMBO J 1998; 17: 384-95. (Pubitemid 28045479)
49. Sun Y, Zhao S, Tian H, et al. Depletion of PI3K p85alpha induces cell cycle arrest and apoptosis in colorectal cancer cells. Oncol Rep 2009; 22: 1435-41.